Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The reversible post‐translational modification of proteins by ubiquitin and ubiquitin‐like proteins regulates almost all cellular processes, by affecting protein degradation, localization, and complex formation. Deubiquitinases ( DUB s) are proteases that remove ubiquitin modifications or cleave ubiquitin chains. Most DUB s are cysteine proteases, which makes them well suited for study by activity‐based probes. These DUB probes report on deubiquitinase activity by reacting covalently with the active site in an enzyme‐catalyzed manner. They have proven to be important tools to study DUB selectivity and proteolytic activity in different settings, to identify novel DUB s, and to characterize deubiquitinase inhibitors. Inspired by the efficacy of activity‐based probes for DUB s, several groups have recently reported probes for the ubiquitin conjugation machinery (E1, E2, and E3 enzymes). Many of these enzymes, while not proteases, also posses active site cysteine residues and can be targeted by covalent probes. In this review, we will discuss how features of the probe (cysteine‐reactive group, recognition element, and reporter tag) affect reactivity and suitability for certain experimental applications. We will also review the diverse applications of the current probes, and discuss the need for new probe types to study emerging aspects of ubiquitin biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 1×
“ABP1 is an analog of pevonedistat (MLN4924), an inhibitor of the NEDD8 E1 enzyme NAE which is currently in clinical trials [110] (Fig.”
BackgroundA multiubiquitin chain is confined to specific lysine in a targeted short-lived protein
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989) · Science · doi:10.1126/science.2538923 · Cited by 1,535 · cited 1×
“Other chain types typically have signaling roles: for example, M1-linked (also called linear) chains are important in several immune signaling pathways [7, 8] .”
BackgroundActivity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy
Bingol, B., Tea, J. S., Phu, L., Reichelt, M., Bakalarski, C. E., Song, Q., Foreman, O., Kirkpatrick, D. S., & Sheng, M. (2014) · Nature · doi:10.1038/nature13418 · Cited by 855 · cited 1×
“ABPP offers an alternative approach to functional genomics techniques, such as overexpression [92] or siRNA [93] screens for DUBs.”
BackgroundThe emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Chemistry-Based Functional Proteomics Reveals Novel Members of the Deubiquitinating Enzyme Family
Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson, K. D., Ploegh, H. L., & Kessler, B. M. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00248-x · Cited by 588 · cited 9×
“Vinyl methyl ester Ub-VME [32] Vinyl cyanide Ub-VCN [32] Thioacrylonitrile Ub-CN [114] Dehydroalanine Ub-Dha-N-methylamide [123] Nucleophilic substitution Chloroethylamine Ub-Cl [32] Bromoethylamine Ub-Br2 [32] Bromopropylamine Ub-Br3 [32] VME showing slightly greater reactivity [32] .”
BackgroundMethodInfluentialThe deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity
Damgaard, R. B., Walker, J. A., Marco-Casanova, P., Morgan, N. V., Titheradge, H. L., Elliott, P. R., McHale, D., Maher, E. R., McKenzie, A. N. J., & Komander, D. (2016) · Cell · doi:10.1016/j.cell.2016.07.019 · Cited by 348 · cited 1×
“There is an increasing interest in M1-linked chains and their corresponding deubiquitinases, which have important roles in inflammation [118, 119] .”
BackgroundActivity-Based Profiling of Proteases
Sanman, L. E., & Bogyo, M. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035352 · Cited by 330 · cited 1×
“A more detailed comparison of substrate-based and activity-based probes has been presented in a recent review [23] .”
BackgroundSelf-citationDiscovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 2×
“In a typical experiment, often referred to as competitive ABPP, cells are incubated with compounds of interest, then lysed and treated with an HA-tagged APB. (Compound treatment can also be performed using lysate [97] .) Comparison with an untreated control indicates the level of inhibition.”
BackgroundMethodOvaa, H., Kessler, B. M., Rolén, U., Galardy, P. J., Ploegh, H. L., & Masucci, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308411100 · Cited by 190
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84 · cited 1×
“Immunomodulatory imide drugs (IMiDs) such as thalidomide are known to target the cullin-RING E3 cereblon, and are approved in hematological malignancies [20] .”
BackgroundDeubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway.
Dar, A., Shibata, E., & Dutta, A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00358-13 · Cited by 83
Cited by
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity
Pao, K.-C., Wood, N. T., Knebel, A., Rafie, K., Stanley, M., Mabbitt, P. D., Sundaramoorthy, R., Hofmann, K., van Aalten, D. M. F., & Virdee, S. (2018) · Nature · doi:10.1038/s41586-018-0026-1 · Cited by 288
Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7.
Lamberto, I., Liu, X., Seo, H.-S., Schauer, N. J., Iacob, R. E., Hu, W., Das, D., Mikhailova, T., Weisberg, E. L., Engen, J. R., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.003 · Cited by 192
“Because in this experiment an irreversible probe (HA-Ub-Vs) is competing for occupancy of USP7 with Cell Chem Biol.”
InfluentialUbiquitin ligation to F-box protein targets by SCF–RBR E3–E3 super-assembly
Horn-Ghetko, D., Krist, D. T., Prabu, J. R., Baek, K., Mulder, M. P. C., Klügel, M., Scott, D. C., Ovaa, H., Kleiger, G., & Schulman, B. A. (2021) · Nature · doi:10.1038/s41586-021-03197-9 · Cited by 187
Kooij, R., Liu, S., Sapmaz, A., Xin, B.-T., Janssen, G. M. C., van Veelen, P. A., Ovaa, H., Dijke, P. T., & Geurink, P. P. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07726 · Cited by 82
Metadata
- Authors
- Hewings, D. S., Flygare, J. A., Bogyo, M., & Wertz, I. E.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2017-03-10
- Volume
- 284
- Issue
- 10
- Pages
- 1555-1576
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W2587794567
- Cited by
- 116
- References
- 12
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.